Current Treatment Options for Fibromyalgia

EP: 1.Impact of Brain on Nociplastic Pain for Fibromyalgia

EP: 2.Approaching Management of Fibromyalgia and Unmet Needs in Treatment

Now Viewing

EP: 3.Current Treatment Options for Fibromyalgia

EP: 4.Treatment Selection and Strategy for Fibromyalgia Agents

EP: 5.Clinical Pearls for the Management of Fibromyalgia

EP: 6.Overview of Fibromyalgia

EP: 7.Challenges for Patients With Fibromyalgia

EP: 8.FDA-Approved Therapies for Fibromyalgia

EP: 9.Treatment Selection in Fibromyalgia

EP: 10.Clinical Pearls for Clinicians Treating Fibromyalgia

EP: 11.Future Developments in Fibromyalgia Treatment

This is a video synopsis of a discussion involving Daniel J. Clauw, MD, a professor of anesthesiology, medicine/rheumatology, and psychiatry at the University of Michigan. Dr. Clauw outlines the pharmacologic options for fibromyalgia, highlighting the three drugs approved by the Food and Drug Administration (FDA) in the United States: duloxetine, pregabalin (gabapentinoid), and milnacipran (norepinephrine, serotonin reuptake inhibitor).

Pregabalin, a gabapentinoid, likely works by reducing the release of excitatory neurotransmitters in the brain, thereby dampening the volume control on pain. Dr. Clauw emphasizes the importance of using gabapentinoids at bedtime to improve sleep depth, crucial for individuals with fibromyalgia. Duloxetine and milnacipran, both serotonin-norepinephrine reuptake inhibitors, differ in their noradrenergic effects, with milnacipran being more noradrenergic. Norepinephrine is deemed crucial for pain reduction and fatigue improvement.

While all three drugs demonstrate efficacy in approximately one out of three to four individuals, their overall effectiveness is as good as it gets in the pain management field. Dr. Clauw acknowledges that real-life experience over the past decade aligns with the data from original trials, indicating that only a subset of individuals continues on these therapies for the long term. The discussion underscores the current state of fibromyalgia pharmacotherapy and the ongoing challenges in achieving optimal outcomes for individuals with fibromyalgia.

Video synopsis is AI-generated and reviewed by HCPLive® editorial staff.